Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 4Phase 2 4Phase NA 3Phase 4 1Phase 2/3 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Conditions

Polycystic Ovary Syndrome 4Hyperandrogenism 3Inflammation 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Spironolactone × Clear all
NCT03068910 2025-08-05

CRM008

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04723862 2025-08-05

CBS010

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04075149 2023-10-27

CBS009

University of Virginia

Phase EARLY_PHASE1 Unknown
24 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed
90 enrolled

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡